Intracameral voriconazole: In vitro safety for human ocular cells

Toxicology

Volumn 258, Issue 2-3, 2009, Pages 84-93

  Kernt, M ^a   Kampik, A ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Amphotericin B; Fungal keratitis; Intracameral drug application; Keratomycosis; Voriconazole

Indexed keywords

HYDROGEN PEROXIDE; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA; VORICONAZOLE;

ADULT; AGED; ARTICLE; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORNEA; CORNEA ENDOTHELIUM; DRUG SAFETY; ENDOTHELIUM CELL; EXPERIMENTAL MODEL; EYE INFLAMMATION; EYE TOXICITY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; OXIDATIVE STRESS; PIGMENT EPITHELIUM; PRIORITY JOURNAL; TOXICITY TESTING; TRABECULAR MESHWORK;

ANTIFUNGAL AGENTS; CELL COUNT; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; CULTURE MEDIA, SERUM-FREE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; ENDOTHELIUM, CORNEAL; EYE; FORMAZANS; HUMANS; HYDROGEN PEROXIDE; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MOLECULAR STRUCTURE; ORGAN CULTURE TECHNIQUES; PIGMENT EPITHELIUM OF EYE; PYRIMIDINES; TETRAZOLIUM SALTS; TIME FACTORS; TRABECULAR MESHWORK; TRIAZOLES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 61349183095     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tox.2009.01.008     Document Type: Article

References (81)

1. Anon., 1978. Natamycin approved-first U.S. drug for fungal keratitis. FDA Drug Bull. 8, 37-38.
2. Axelrod A.J., Peyman G.A., and Apple D.J. Toxicity of intravitreal injection of amphotericin B. Am. J. Ophthalmol. 76 (1973) 578-583
3. Bednarz J., Teifel M., Friedl P., and Engelmann K. Immortalization of human corneal endothelial cells using electroporation protocol optimized for human corneal endothelial and human retinal pigment epithelial cells. Acta Ophthalmol. Scand. 78 (2000) 130-136
4. Benz M.S., Scott I.U., Flynn Jr. H.W., Unonius N., and Miller D. Endophthalmitis isolates and antibiotic sensitivities: a 6-year review of culture-proven cases. Am. J. Ophthalmol. 137 (2004) 38-42
5. Bernal M.D., Acharya N.R., Lietman T.M., Strauss E.C., McLeod S.D., and Hwang D.G. Outbreak of Fusarium keratitis in soft contact lens wearers in San Francisco. Arch. Ophthalmol. 124 (2006) 1051-1053
6. Bohnke M. A new system for storing donor corneas. Klin Monatsbl Augenheilkd 198 (1991) 135-137
7. Bourne W.M., and Kaufman H.E. The endothelium of clear corneal transplants. Arch. Ophthalmol. 94 (1976) 1730-1732
8. Bunya V.Y., Hammersmith K.M., Rapuano C.J., Ayres B.D., and Cohen E.J. Topical and oral voriconazole in the treatment of fungal keratitis. Am. J. Ophthalmol. 143 (2007) 151-153
9. Chalam K.V., Gupta S.K., Grover S., Brar V.S., and Agarwal S. Intracameral Avastin dramatically resolves iris neovascularization and reverses neovascular glaucoma. Eur. J. Ophthalmol. 18 (2008) 255-262
10. Chen F.K., Chen S.D., and Tay-Kearney M.L. Intravitreal voriconazole for the treatment of endogenous endophthalmitis caused by Scedosporium apiospermum. Clin. Exp. Ophthalmol. 35 (2007) 382-385
11. Clements Jr. J.S., and Peacock Jr. J.E. Amphotericin B revisited: reassessment of toxicity. Am. J. Med. 88 (1990) 22N-27N
12. Creti A., Esposito V., Bocchetti M., Baldi G., De Rosa P., Parrella R., and Chirianni A. Voriconazole curative treatment for Acremonium species keratitis developed in a patient with concomitant Staphylococcus aureus corneal infection: a case report. In Vivo 20 (2006) 169-171
13. Dunlop A.A., Wright E.D., Howlader S.A., Nazrul I., Husain R., McClellan K., and Billson F.A. Suppurative corneal ulceration in Bangladesh. A study of 142 cases examining the microbiological diagnosis, clinical and epidemiological features of bacterial and fungal keratitis. Aust. N.Z. J. Ophthalmol. 22 (1994) 105-110
14. Durand M.L., Kim I.K., D'Amico D.J., Loewenstein J.I., Tobin E.H., Kieval S.J., Martin S.S., Azar D.T., Miller III F.S., Lujan B.J., and Miller J.W. Successful treatment of Fusarium endophthalmitis with voriconazole and Aspergillus endophthalmitis with voriconazole plus caspofungin. Am. J. Ophthalmol. 140 (2005) 552-554
15. Ejdervik-Lindblad B., Lindberg M., and Hakansson E.B. Enterococcal endophthalmitis following cataract extraction, treated with ampicillin intravitreally. Acta Ophthalmol. (Copenh.) 70 (1992) 842-843
16. Endophthalmitis Study Group, European Society of Cataract & Refractive Surgeons, 2007. Prophylaxis of postoperative endophthalmitis following cataract surgery: results of the ESCRS multicenter study and identification of risk factors. J. Cataract. Refract. Surg. 33, 978-988.
17. Espinel-Ingroff A., Boyle K., and Sheehan D.J. In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature. Mycopathologia 150 (2001) 101-115
18. Essman T.F., Flynn Jr. H.W., Smiddy W.E., Brod R.D., Murray T.G., Davis J.L., and Rubsamen P.E. Treatment outcomes in a 10-year study of endogenous fungal endophthalmitis. Ophthal. Surg. Lasers 28 (1997) 185-194
19. Feys J., Emond J.P., Salvanet-Bouccara A., and Dublanchet A. Interleukin-6 and other cytokines in the aqueous humor in uveitis and endophthalmitis. J. Fr. Ophtalmol. 17 (1994) 634-639
20. Florcruz N.V., and Peczon Jr. I. Medical interventions for fungal keratitis. Cochrane Database Syst. Rev. (2008) CD004241
21. Freda R. Use of oral voriconazole as adjunctive treatment of severe cornea fungal infection: case report. Arq. Bras. Oftalmol. 69 (2006) 431-434
22. Gallis H.A., Drew R.H., and Pickard W.W. Amphotericin B: 30 years of clinical experience. Rev. Infect. Dis. 12 (1990) 308-329
23. Gao H., Pennesi M.E., Shah K., Qiao X., Hariprasad S.M., Mieler W.F., Wu S.M., and Holz E.R. Intravitreal voriconazole: an electroretinographic and histopathologic study. Arch. Ophthalmol. 122 (2004) 1687-1692
24. Ghannoum M.A., and Kuhn D.M. Voriconazole-better chances for patients with invasive mycoses. Eur. J. Med. Res. 7 (2002) 242-256
25. Giese M.J., Sumner H.L., Berliner J.A., and Mondino B.J. Cytokine expression in a rat model of Staphylococcus aureus endophthalmitis. Invest. Ophthalmol. Vis. Sci. 39 (1998) 2785-2790
26. Hariprasad S.M., Mieler W.F., Holz E.R., Gao H., Kim J.E., Chi J., and Prince R.A. Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans. Arch. Ophthalmol. 122 (2004) 42-47
27. Haritoglou C., Yu A., Freyer W., Priglinger S.G., Alge C., Eibl K., May C.A., Welge-Luessen U., and Kampik A. An evaluation of novel vital dyes for intraocular surgery. Invest. Ophthalmol. Vis. Sci. 46 (2005) 3315-3322
28. Herbrecht R. Voriconazole: therapeutic review of a new azole antifungal. Expert Rev. Anti Infect. Ther. 2 (2004) 485-497
29. Hoshino K., Takeuchi O., Kawai T., Sanjo H., Ogawa T., Takeda Y., Takeda K., and Akira S. Cutting edge: toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the LPS gene product. J. Immunol. 162 (1999) 3749-3752
30. Kailasanathan A., and Anderson D.F. Infectious crystalline keratopathy caused by Gemella haemolysans. Cornea 26 (2007) 643-644
31. Karalezli A., Borazan M., and Akova Y.A. Intracameral triamcinolone acetonide to control postoperative inflammation following cataract surgery with phacoemulsification. Acta Ophthalmol. 86 (2008) 183-187
32. Kaufman H.E., and Katz J.I. Pathology of the corneal endothelium. Invest. Ophthalmol. Vis. Sci. 16 (1977) 265-268
33. Kaushik S., Ram J., Brar G.S., Jain A.K., Chakraborti A., and Gupta A. Intracameral amphotericin B: initial experience in severe keratomycosis. Cornea 20 (2001) 715-719
34. Kawashima H. Chemokines-their role in immunotherapy for intraocular inflammation. Ocul. Immunol. Inflamm. 11 (2003) 83-90
35. Kernt M., Neubauer A.S., Ulbig M.W., Kampik A., and Welge-Lussen U. In vitro safety of intravitreal moxifloxacin for endophthalmitis treatment. J. Cataract Refract. Surg. 34 (2008) 480-488
36. Kernt M., Welge-Lussen U., Yu A., Neubauer A.S., and Kampik A. Bevacizumab is not toxic to human anterior- and posterior-segment cultured cells. Ophthalmologe 104 (2007) 965-971
37. Khan M.U., Haque E., and Khan M.R. Prevalence & causes of blindness in rural Bangladesh. Indian J. Med. Res. 82 (1985) 257-262
38. Klont R.R., Eggink C.A., Rijs A.J., Wesseling P., and Verweij P.E. Successful treatment of Fusarium keratitis with cornea transplantation and topical and systemic voriconazole. Clin. Infect. Dis. 40 (2005) e110-e112
39. Kramer M., Kramer M.R., Blau H., Bishara J., Axer-Siegel R., and Weinberger D. Intravitreal voriconazole for the treatment of endogenous Aspergillus endophthalmitis. Ophthalmology 113 (2006) 1184-1186
40. Kuriakose T., Kothari M., Paul P., Jacob P., and Thomas R. Intracameral amphotericin B injection in the management of deep keratomycosis. Cornea 21 (2002) 653-656
41. Lalitha P., Prajna N.V., Kabra A., Mahadevan K., and Srinivasan M. Risk factors for treatment outcome in fungal keratitis. Ophthalmology 113 (2006) 526-530
42. Laurell C.G., and Lydahl E. Evaluation of aqueous outflow facility in patients with high intraocular pressure after cataract surgery. Ophthalmic Surg. Lasers Imaging 37 (2006) 476-480
43. Liesegang T.J., and Forster R.K. Spectrum of microbial keratitis in South Florida. Am. J. Ophthalmol. 90 (1980) 38-47
44. Lin R.C., Sanduja N., and Hariprasad S.M. Successful treatment of postoperative fungal endophthalmitis using intravitreal and intracameral voriconazole. J. Ocul. Pharmacol. Ther. 24 (2008) 245-248
45. Marangon F.B., Miller D., Giaconi J.A., and Alfonso E.C. In vitro investigation of voriconazole susceptibility for keratitis and endophthalmitis fungal pathogens. Am. J. Ophthalmol. 137 (2004) 820-825
46. McKelvie P.A., Wong E.Y., Chow L.P., and Hall A.J. Scedosporium endophthalmitis: two fatal disseminated cases of Scedosporium infection presenting with endophthalmitis. Clin. Exp. Ophthalmol. 29 (2001) 330-334
47. Miller P.E., Stanz K.M., Dubielzig R.R., and Murphy C.J. Mechanisms of acute intraocular pressure increases after phacoemulsification lens extraction in dogs. Am. J. Vet. Res. 58 (1997) 1159-1165
48. Mo J.S., and Streilein J.W. Immune privilege persists in eyes with extreme inflammation induced by intravitreal LPS. Eur. J. Immunol. 31 (2001) 3806-3815
49. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65 (1983) 55-63
50. Nehemy M.B., Vasconcelos-Santos D.V., Torqueti-Costa L., and Magalhaes E.P. Chronic endophthalmitis due to verticillium species after cataract surgery treated (or managed) with pars plana vitrectomy and oral and intravitreal voriconazole. Retina 26 (2006) 225-227
51. O'Day D.M., Head W.S., Robinson R.D., and Clanton J.A. Corneal penetration of topical amphotericin B and natamycin. Curr. Eye Res. 5 (1986) 877-882
52. Ozbek Z., Kang S., Sivalingam J., Rapuano C.J., Cohen E.J., and Hammersmith K.M. Voriconazole in the management of Alternaria keratitis. Cornea 25 (2006) 242-244
53. Polack F.M., Kaufman H.E., and Newmark E. Keratomycosis. Medical and surgical treatment. Arch. Ophthalmol. 85 (1971) 410-416
54. Rapoza P.A., West S.K., Katala S.J., and Taylor H.R. Prevalence and causes of vision loss in central Tanzania. Int. Ophthalmol. 15 (1991) 123-129
55. Reddy P.S., Satyendran O.M., Satapathy M., Kumar H.V., and Reddy P.R. Mycotic keratitis. Indian J. Ophthalmol. 20 (1972) 101-108
56. Rosa Jr. R.H., Miller D., and Alfonso E.C. The changing spectrum of fungal keratitis in south Florida. Ophthalmology 101 (1994) 1005-1013
57. Satofuka S., Ichihara A., Nagai N., Yamashiro K., Koto T., Shinoda H., Noda K., Ozawa Y., Inoue M., Tsubota K., Suzuki F., Oike Y., and Ishida S. Suppression of ocular inflammation in endotoxin-induced uveitis by inhibiting nonproteolytic activation of prorenin. Invest. Ophthalmol. Vis. Sci. 47 (2006) 2686-2692
58. Sen P., Gopal L., and Sen P.R. Intravitreal voriconazole for drug-resistant fungal endophthalmitis: case series. Retina 26 (2006) 935-939
59. Siegner A., May C.A., Welge-Lussen U.W., Bloemendal H., and Lutjen-Drecoll E. Alpha B-crystallin in the primate ciliary muscle and trabecular meshwork. Eur. J. Cell Biol. 71 (1996) 165-169
60. Souri E.N., and Green W.R. Intravitreal amphotericin B toxicity. Am. J. Ophthalmol. 78 (1974) 77-81
61. Sponsel W., Chen N., Dang D., Paris G., Graybill J., Najvar L.K., Zhou L., Lam K.W., Glickman R., and Scribbick F. Topical voriconazole as a novel treatment for fungal keratitis. Antimicrob. Agents Chemother. 50 (2006) 262-268
62. Sridhar M.S., Sharma S., Gopinathan U., and Rao G.N. Anterior chamber tap: diagnostic and therapeutic indications in the management of ocular infections. Cornea 21 (2002) 718-722
63. Srinivasan M. Fungal keratitis. Curr. Opin. Ophthalmol. 15 (2004) 321-327
64. Srinivasan M., Gonzales C.A., George C., Cevallos V., Mascarenhas J.M., Asokan B., Wilkins J., Smolin G., and Whitcher J.P. Epidemiology and aetiological diagnosis of corneal ulceration in Madurai, south India. Br. J. Ophthalmol. 81 (1997) 965-971
65. Thomas J., Kanangat S., and Rouse B.T. Herpes simplex virus replication-induced expression of chemokines and proinflammatory cytokines in the eye: implications in herpetic stromal keratitis. J. Interferon Cytokine Res. 18 (1998) 681-690
66. Thomas P.A. Mycotic keratitis-an underestimated mycosis. J. Med. Vet. Mycol. 32 (1994) 235-256
67. Thomas P.A. Fungal infections of the cornea. Eye 17 (2003) 852-862
68. Thylefors B., Negrel A.D., Pararajasegaram R., and Dadzie K.Y. Available data on blindness (update 1994). Ophthalmic Epidemiol. 2 (1995) 5-39
69. Thylefors B.I. The WHO programme for the prevention of blindness. Ophthalmic Epidemiol. 1 (1994) 3-4
70. Tracey K.J., and Cerami A. Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. Annu. Rev. Med. 45 (1994) 491-503
71. Tu K.L., Kaye S.B., Sidaras G., Taylor W., and Shenkin A. Effect of intraocular surgery and ketamine on aqueous and serum cytokines. Mol. Vis. 13 (2007) 1130-1137
72. Upadhyay M.P., Karmacharya P.C., Koirala S., Tuladhar N.R., Bryan L.E., Smolin G., and Whitcher J.P. Epidemiologic characteristics, predisposing factors, and etiologic diagnosis of corneal ulceration in Nepal. Am. J. Ophthalmol. 111 (1991) 92-99
73. Vemulakonda G.A., Hariprasad S.M., Mieler W.F., Prince R.A., Shah G.K., and Van Gelder R.N. Aqueous and vitreous concentrations following topical administration of 1% voriconazole in humans. Arch. Ophthalmol. 126 (2008) 18-22
74. Welge-Lussen U., Eichhorn M., Bloemendal H., and Lutjen-Drecoll E. Classification of human scleral spur cells in monolayer culture. Eur. J. Cell Biol. 75 (1998) 78-84
75. Wellington M., and Gigliotti F. Update on antifungal agents. Pediatr. Infect. Dis. J. 20 (2001) 993-995
76. Williams G., McClellan K., and Billson F. Suppurative keratitis in rural Bangladesh: the value of gram stain in planning management. Int. Ophthalmol. 15 (1991) 131-135
77. Wood T.O., and Williford W. Treatment of keratomycosis with amphotericin B 0.15%. Am. J. Ophthalmol. 81 (1976) 847-849
78. Wykoff C.C., Flynn Jr. H.W., Miller D., Scott I.U., and Alfonso E.C. Exogenous fungal endophthalmitis: microbiology and clinical outcomes. Ophthalmology (2008)
79. Yildiran S.T., Mutlu F.M., Saracli M.A., Uysal Y., Gonlum A., Sobaci G., and Sutton D.A. Fungal endophthalmitis caused by Aspergillus ustus in a patient following cataract surgery. Med. Mycol. 44 (2006) 665-669
80. Yilmaz S., Ture M., and Maden A. Efficacy of intracameral amphotericin B injection in the management of refractory keratomycosis and endophthalmitis. Cornea 26 (2007) 398-402
81. Yoon K.C., Jeong I.Y., Im S.K., Chae H.J., and Yang S.Y. Therapeutic effect of intracameral amphotericin B injection in the treatment of fungal keratitis. Cornea 26 (2007) 814-818